News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Orexo AB Successfully Completes OX219 Dose Proportionality Study Ahead of Schedule


6/19/2012 11:05:53 AM

UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (“Orexo”) (STO:ORX) today announced the successful completion of the dose proportionality study for OX219. OX219 is a sublingual formulation of buprenorphine and naloxone, which employs Orexo’s proprietary technologies, and is intended for maintenance treatment of patients suffering from opioid-dependence.

Read at BioSpace.com

comments powered by Disqus
Orexo AB
 
 
Addiction

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES